Patents by Inventor Olga Popova
Olga Popova has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220305111Abstract: The invention relates to biotechnology, immunology and virology and, in particular, to an immunobiological agent for the prevention of diseases caused by severe acute respiratory syndrome virus SARS-CoV-2. Also, a method of inducing specific immunity to the SARS-CoV-2 virus is disclosed, comprising the administration to mammals of one or more immunobiological agents for the prevention of diseases caused by severe acute respiratory syndrome virus SARS-CoV-2. The invention facilitates an effective induction of the immune response to the SARS-CoV-2 virus.Type: ApplicationFiled: July 13, 2020Publication date: September 29, 2022Applicant: FEDERAL STATE BUDGETARY INSTITUTION "NATIONAL RESEARCH CENTER FOR EPIDEMIOLOGY AND MICROBIOLOGYInventors: Olga Vadimovna ZUBKOVA, Tatiana Andreevna OZHAROVSKAIA, Inna Vadimovna DOLZHIKOVA, Olga POPOVA, Dmitrii Viktorovich SHCHEBLIAKOV, Daria Mikhailovna GROUSOVA, Alina Shahmirovna DZHARULLAEVA, Amir Ildarovich TUKHVATULIN, Natalia Mikhailovna TUKHVATULINA, Dmitrii Nikolaevich SHCHERBININ, Ilias Bulatovich ESMAGAMBETOV, Elizaveta Alexandrovna TOKARSKAYA, Andrei Gennadevich BOTIKOV, Sergey Vladimirovich BORISEVICH, Boris Savelievich NARODITSKY, Denis Yuryevich LOGUNOV, Aleksandr Leonidovich GINTSBURG
-
Publication number: 20220265816Abstract: The disclosed invention relates to safe and efficacious methods of extending postvaccinal immunity against severe acute respiratory syndrome virus SARS-CoV-2 and revaccinating a population against diseases caused by SARS-CoV-2. The disclosed methods include administration of an agent to a person or population. The agent may include a first component comprising an expression vector based on a genome of recombinant strain of (i) human adenovirus serotype 26 with the E1 and E3 sites deleted from the genome and the site ORF6-Ad26 substituted for ORF6-Ad5 with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3, or (ii) a simian adenovirus serotype 25 with the E1 and E3 sites deleted from the genome with an integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, or SEQ ID NO:3.Type: ApplicationFiled: April 15, 2022Publication date: August 25, 2022Inventors: Olga Vadimovna ZUBKOVA, Tatiana Andreevna OZHAROVSKAIA, Inna Vadimovna DOLZHIKOVA, Olga POPOVA, Dmitrii Viktorovich SHCHEBLIAKOV, Daria Mikhailovna GROUSOVA, Alina Shahmirovna DZHARULLAEVA, Amir Ildarovich TUKHVATULIN, Natalia Mikhailovna TUKHVATULINA, Dmitrii Nikolaevich SHCHERBININ, Ilias Bulatovich ESMAGAMBETOV, Elizaveta Alexsandrovna TOKARSKAYA, Andrei Gennadevich BOTIKOV, Alina Sergeevna EROXOVA, Fatima Magometovna IZHAEVA, Natalya Anatolevna NIKITENKO, Nadezhda Leonidovna LUBENETS, Aleksandr Sergeevich SEMIKHIN, Vladimir Aleksandrovich CHERNETSOV, Evgenii Vladimirovich KRIUKOV, Vladimir Fedorovich BABIRA, Dmitrii Anatolevich KUTAEV, Svetlana Iakovlevna LOGINOVA, Boris Savelievich NARODITSKY, Denis Yuryevich LOGUNOV, Aleksandr Leonidovich GINTSBURG
-
Publication number: 20220259618Abstract: The invention relates to a biomolecule agent for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2, in liquid form, which contains a single active component, comprising the expression vector including either: the genome of the recombinant strain of human adenovirus serotype 26 or 5, wherein the E1 and E3 regions are deleted, the vector with an integrated expression cassette is selected from SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3; or the recombinant strain of simian adenovirus serotype 25, wherein the E1 and E3 regions are deleted, the vector with an integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, or SEQ ID NO:3. The recombinant strain of human adenovirus serotype 26 may include the ORF6-Ad26 region replaced by ORF6-Ad5. A buffer solution of the agent in liquid form contains the following, by mass %: tris from 0.1831 to 0.3432; sodium chloride from 0.3313-0.6212; sucrose from 3.7821-7.0915; magnesium chloride hexahydrate from 0.0154-0.Type: ApplicationFiled: April 12, 2022Publication date: August 18, 2022Inventors: Olga Vadimovna ZUBKOVA, Tatiana Andreevna OZHAROVSKAIA, Inna Vadimovna DOLZHIKOVA, Olga POPOVA, Dmitrii Viktorovich SHCHEBLIAKOV, Daria Mikhailovna GROUOVA, Alina Shahmirovna DZHARULLAEVA, Amir Ildarovich TUKHVATULIN, Natalia Mikhailovna TUKHVATULINA, Dmitrii Nikolaevich SHCHERBININ, Ilias Bulatovich ESMAGAMBETOV, Elizaveta Alexsandrovna TOKARSKAYA, Andrei Gennadevich BOTIKOV, Alina Sergeevna EROXOVA, Fatima Magometovna IZHAEVA, Natalya Anatolevna NIKITENKO, Nadezhda Leonidovna LUBENETS, Aleksandr Sergeevich SEMIKHIN, Sergey Vladimirovich BORISEVICH, Boris Savelievich NARODITSKY, Denis Yuryevich LOGUNOV, Aleksandr Leonidovich GINTSBURG
-
Publication number: 20220249655Abstract: The invention relates to a biomolecule agent for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2, in lyophilized (freeze-dried) form, which contains a single active component, comprising the expression vector including either the genome of the recombinant strain of human adenovirus serotype 26 or 5, wherein the E1 and E3 regions are deleted, and an integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3; or the genome of the recombinant strain of simian adenovirus serotype 25, wherein the E1 and E3 regions are deleted, and an integrated expression cassette is selected from SEQ ID NO:4, SEQ ID NO:2, or SEQ ID NO:3. The genome of the recombinant strain of human adenovirus serotype 26 may include the ORF6-Ad26 region replaced by ORF6-Ad5. A buffer solution for reconstitution of the lyophilized form of the agent may contain the following, mass %: tris from 0.0180-0.0338; sodium chloride from 0.1044-0.1957; sucrose from 5.4688-10.Type: ApplicationFiled: April 7, 2022Publication date: August 11, 2022Inventors: Olga Vadimovna Zubkova, Tatiana Andreevna Ozharovskaia, Inna Vadimovna Dolzhikova, Olga Popova, Dmitrii Viktorovich Shchebliakov, Daria Mikhailovna Grousova, Alina Shahmirovna Dzharullaeva, Amir Ildarovich Tukhvatulin, Natalia Mikhailovna Tukhvatulina, Dmitrii Nikolaevich Shcherbinin, Ilias Bulatovich Esmagambetov, Elizaveta Alexsandrovna Tokarskaya, Andrei Gennadevich Botikov, Alina Sergeevna Eroxova, Fatima Magometovna Izhaeva, Natalya Anatolevna Nikitenko, Nadezhda Leonidovna Lubenets, Aleksandr Sergeevich Semikhin, Sergey Vladimirovich Borisevich, Boris Savelievich Naroditsky, Denis Yuryevich Logunov, Aleksandr Leonidovich Gintsburg
-
Publication number: 20220235376Abstract: The invention relates to preparing and using recombinant expression vectors for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2. One expression vector contains the recombinant human adenovirus serotype26 genome, wherein the E1 and E3 regions are deleted, and the ORF6-Ad26 region is replaced by ORF6-Ad5, with an integrated expression cassette of SEQ ID NO:1, 2, or 3 (variant 1). Therein, SEQ ID NO:5 was a parental sequence of human adenovirus serotype 26. Another expression vector contains the recombinant simian adenovirus serotype25 genome, wherein the E1 and E3 regions are deleted, with an integrated expression cassette of SEQ ID NO:4, 2, or 3 (variant 2). Therein, SEQ ID NO:6 was a parental sequence of simian adenovirus serotype 25. Further, the recombinant human adenovirus serotype5 genome is disclosed, wherein the E1 and E3 regions are deleted, with an integrated expression cassette of SEQ ID NO:1, 2, or 3 (variant 3).Type: ApplicationFiled: March 31, 2022Publication date: July 28, 2022Inventors: Olga Vadimovna ZUBKOVA, Tatiana Andreevna Ozharovskaia, Inna Vadimovna Dolzhikova, Olga Popova, Dmitrii Viktorovich Shchebliakov, Daria Mikhailovna Grousova, Alina Shahmirovna Dzharullaeva, Amir IIdarovich Tukhvatulin, Natalia Mikhailovna Tukhvatulina, Dmitrii Nikolaevich Shcherbinin, IIias Bulatovich Esmagambetov, Elizaveta Alexsandrovna Tokarskaya, Andrei Gennadevich Botikov, Alina Sergeevna Eroxova, Natalya Anatolevna Nikitenko, Aleksandr Sergeevich Semikhin, Sergey Vladimirovich Borisevich, Boris Savelievich Naroditsky, Denis Yuryevich Logunov, Aleksandr Leonidovich Gintsburg
-
Publication number: 20220226466Abstract: The invention relates to biotechnology. The claimed agent can be used for the prevention of SARS-CoV-2. A pharmaceutical agent may contain component (1), and contains a recombinant human adenovirus serotype genome (26), with an expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3, and also contains component (2), comprising an agent selected from (i) a recombinant human adenovirus serotype genome (5), with an expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3; or (ii) a recombinant simian adenovirus serotype genome (25), with an expression cassette selected from SEQ ID NO: 4, SEQ ID NO: 2, or SEQ ID NO: 3.Type: ApplicationFiled: April 7, 2022Publication date: July 21, 2022Inventors: Olga Vadimovna ZUBKOVA, Tatiana Andreevna OZHAROVSKAIA, Inna Vadimovna DOLZHIKOVA, Olga POPOVA, Dmitrii Viktorovich SHCHEBLIAKOV, Daria Mikhailovna GROUSOVA, Alina Shahmirovna DZHARULLAEVA, Amir Ildarovich TUKHAVTULIN, Natalia Mikhailovna TUKHVATULINA, Dmitrii Nikolaevich SHCHERBININ, Ilias Bulatovich ESMAGAMBETOV, Elizaveta Alexsandrovna TOKARSKAYA, Andrei Gennadevich BOTIKOV, Alina Sergeevna EROXOVA, Fatima Magometovna IZHAEVA, Aleksandr Sergeevich SEMIKHIN, Sergey Vladimirovich BORISEVICH, Boris Savelievich NARODITSKY, Denis Yuryevich LOGUNOV, Aleksandr Leonidovich GINTSBURG
-
Publication number: 20190167780Abstract: The invention provides a vaccine for protecting a human patient against infection by a human influenza virus strain, wherein the vaccine comprises an antigen from an avian influenza virus strain that can cause highly pathogenic avian influenza. The antigen can invoke an antibody response in the patient that is capable of neutralising said human influenza virus strain. Whereas the prior art used known non-pathogenic avian strains to generate antibodies in humans against known pathogenic avian strains, the invention uses known pathogenic avian strains to protect against emerging pathogenic human strains. Furthermore, whereas the prior art focused on achieving a close antigenic match between the vaccine strain and the target strain, the invention selects vaccine strains based on their pathogenicity, regardless of any perceived close antigenic relationship to the target strain.Type: ApplicationFiled: July 11, 2018Publication date: June 6, 2019Inventors: Audino PODDA, Olga Popova, Francesca Piccinetti
-
Publication number: 20080254065Abstract: The invention provides a vaccine for protecting a human patient against infection by a human influenza virus strain, wherein the vaccine comprises an antigen from an avian influenza virus strain that can cause highly pathogenic avian influenza. The antigen can invoke an antibody response in the patient that is capable of neutralising said human influenza virus strain. Whereas the prior art used known non-pathogenic avian strains to generate antibodies in humans against known pathogenic avian strains, the invention uses known pathogenic avian strains to protect against emerging pathogenic human strains. Furthermore, whereas the prior art focused on achieving a close antigenic match between the vaccine strain and the target strain, the invention selects vaccine strains based on their pathogenicity, regardless of any perceived close antigenic relationship to the target strain.Type: ApplicationFiled: March 9, 2005Publication date: October 16, 2008Applicant: CHIRON CORPORATIONInventors: Audino Podda, Olga Popova, Francesca Piccinetti